Pfizer Inc. (NYSE:PFE) Shares Sold by Waterloo Capital L.P.

Waterloo Capital L.P. cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 67.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 20,232 shares of the biopharmaceutical company’s stock after selling 41,162 shares during the period. Waterloo Capital L.P.’s holdings in Pfizer were worth $566,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Cantor Fitzgerald Investment Advisors L.P. acquired a new position in Pfizer during the fourth quarter valued at $16,166,000. LGT Group Foundation boosted its holdings in Pfizer by 2.5% during the second quarter. LGT Group Foundation now owns 742,875 shares of the biopharmaceutical company’s stock worth $20,786,000 after buying an additional 18,274 shares in the last quarter. ORG Partners LLC grew its position in Pfizer by 1,729.9% during the second quarter. ORG Partners LLC now owns 47,028 shares of the biopharmaceutical company’s stock valued at $1,327,000 after buying an additional 44,458 shares during the period. Kempner Capital Management Inc. purchased a new position in Pfizer in the first quarter valued at $2,439,000. Finally, Leo Wealth LLC acquired a new position in shares of Pfizer in the fourth quarter worth about $2,171,000. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Down 0.3 %

Shares of PFE opened at $29.75 on Thursday. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $34.11. The company has a quick ratio of 0.60, a current ratio of 0.86 and a debt-to-equity ratio of 0.65. The firm’s fifty day moving average is $29.33 and its two-hundred day moving average is $28.19. The stock has a market cap of $168.58 billion, a PE ratio of -495.75, a price-to-earnings-growth ratio of 1.02 and a beta of 0.68.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.46 by $0.14. Pfizer had a negative net margin of 4.66% and a positive return on equity of 8.42%. The company had revenue of $13.28 billion for the quarter, compared to analysts’ expectations of $12.96 billion. During the same quarter in the previous year, the company posted $0.67 EPS. The firm’s quarterly revenue was up 2.1% on a year-over-year basis. Research analysts forecast that Pfizer Inc. will post 2.66 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were issued a dividend of $0.42 per share. The ex-dividend date of this dividend was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.65%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. Daiwa Capital Markets upgraded Pfizer from a “neutral” rating to an “outperform” rating and raised their target price for the company from $28.00 to $34.00 in a research report on Wednesday, August 7th. Wells Fargo & Company boosted their price objective on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. Barclays increased their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group lifted their price target on shares of Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a research note on Wednesday, July 31st. Finally, Daiwa America raised shares of Pfizer from a “moderate buy” rating to a “strong-buy” rating in a research note on Wednesday, August 7th. Eight analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, Pfizer currently has a consensus rating of “Moderate Buy” and an average target price of $34.54.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.